CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($1.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.06), Briefing.com reports. The company had revenue of $0.52 million for the quarter, compared to the consensus estimate of $12.31 million. The company’s revenue was down 99.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.98) earnings per share.
CRISPR Therapeutics Stock Down 2.8 %
NASDAQ:CRSP opened at $49.66 on Tuesday. The company has a fifty day moving average of $57.20 and a 200 day moving average of $63.27. CRISPR Therapeutics has a 52 week low of $37.55 and a 52 week high of $91.10. The firm has a market capitalization of $4.22 billion, a P/E ratio of -18.26 and a beta of 1.70.
Insider Activity at CRISPR Therapeutics
In related news, COO Julianne Bruno sold 3,366 shares of the stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the sale, the chief operating officer now directly owns 6,745 shares of the company’s stock, valued at approximately $378,327.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.10% of the stock is currently owned by company insiders.
Analyst Ratings Changes
View Our Latest Research Report on CRISPR Therapeutics
CRISPR Therapeutics Company Profile
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Recommended Stories
- Five stocks we like better than CRISPR Therapeutics
- What Are Dividends? Buy the Best Dividend Stocks
- Berkshire Hathaway Cuts Bank of America Stake: What to Know
- When to Sell a Stock for Profit or Loss
- Carvana Hits Record Milestones in Q2 With More to Come in 2024
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Why Intuitive Surgical Stock is Dominating the Medical Sector
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.